| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg | |||
| Other Sizes |
| Targets |
Nrf2 activator-4 targets the transcription factor Nrf2 (nuclear factor erythroid 2-related factor 2), a master regulator of the antioxidant response. Nrf2 binds to the antioxidant response element (ARE) in the promoter region of genes encoding antioxidant enzymes (e.g., HO-1, NQO1, SOD) and detoxifying enzymes. The compound activates Nrf2 with an EC50 of 0.63 μM. By activating Nrf2, it upregulates the expression of cytoprotective genes and suppresses reactive oxygen species against oxidative stress in microglia. It has potential therapeutic applications in neurodegenerative diseases and metabolic disorders.
|
|---|---|
| ln Vitro |
In vitro, Nrf2 activator-4 activates Nrf2 with an EC50 of 0.63 μM. It suppresses reactive oxygen species (ROS) production against oxidative stress in microglia, demonstrating potent antioxidant activity. The compound upregulates the expression of Nrf2 target genes such as HO-1 and NQO1 in various cell types. It shows neuroprotective effects in cellular models of oxidative stress. In hepatocytes or other relevant cell lines, it may protect against metabolic dysfunction-associated oxidative damage.
|
| ln Vivo |
In vivo, Nrf2 activator-4 has potential applications in treating Alzheimer's disease and metabolic dysfunction-associated fatty liver disease. In scopolamine-induced mouse models, the compound may ameliorate learning and memory impairment, suggesting neuroprotective effects. It is orally active, making it suitable for oral administration. However, specific in vivo efficacy data for this compound are not extensively detailed in the available literature.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for Nrf2 activator-4 typically involve ARE-luciferase reporter assays or Nrf2 protein stabilization assays. Cells (e.g., HEK293 or HepG2) are transfected with a plasmid containing the ARE sequence upstream of a luciferase reporter gene. Cells are treated with various concentrations of the compound (typically 0.001-10 μM) for 6-24 hours. Luciferase activity is measured using a luminometer. The EC50 for Nrf2 activation is determined from dose-response curves. Nrf2 protein levels can be assessed by Western blotting.
|
| Cell Assay |
In vitro cellular assays for Nrf2 activator-4 use microglial cell lines (e.g., BV2 or primary microglia) to assess ROS suppression. Cells are cultured in DMEM with 10% FBS and pre-treated with various concentrations of the compound (typically 0.01-10 μM) for 2-4 hours, followed by exposure to an oxidative stress inducer (e.g., H2O2 or LPS) for 6-24 hours. Intracellular ROS levels are measured using DCFH-DA staining and flow cytometry or fluorescence microscopy. Nrf2 target gene expression (HO-1, NQO1) is analyzed by qPCR. Cell viability is assessed using MTT assays.
|
| Animal Protocol |
In vivo animal studies with Nrf2 activator-4 typically use mouse models of Alzheimer's disease or metabolic dysfunction. In scopolamine-induced memory impairment models, mice are administered the compound orally at doses of 1-30 mg/kg for 7-14 days. Cognitive function is assessed by Morris water maze or novel object recognition tests. Brain tissue is analyzed for oxidative stress markers (MDA, GSH), Nrf2 target gene expression, and neuroinflammation markers. In fatty liver disease models, mice are fed a high-fat diet and treated with the compound for 4-8 weeks, followed by assessment of liver histology and serum lipids.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Nrf2 activator-4: The compound is orally active, suggesting good oral bioavailability. Specific PK parameters such as Cmax, Tmax, AUC, half-life, and tissue distribution are not extensively reported in the available literature. The compound has a molecular weight of 468.90 and is expected to be metabolized by hepatic CYP450 enzymes. Further pharmacokinetic characterization would be needed for detailed understanding.
|
| Toxicity/Toxicokinetics |
The toxicity profile of Nrf2 activator-4 is not extensively reported in the available literature. As an Nrf2 activator, it is expected to have a favorable safety profile due to its cytoprotective mechanism. The compound is for research use only and not for human therapeutic use. Standard toxicity studies would include acute and subchronic oral toxicity in rodents, with monitoring of body weight, clinical signs, hematology, clinical chemistry, and histopathology. No specific genotoxicity or cardiotoxicity data are reported.
|
| References | |
| Additional Infomation |
Nrf2 activator-4 (CAS 2383016-68-8, Compound 20a) is a highly potent, orally active Nrf2 activator with an EC50 of 0.63 μM. It suppresses reactive oxygen species against oxidative stress in microglia and has potential therapeutic applications in Alzheimer's disease and metabolic dysfunction-associated fatty liver disease. The compound is a valuable research tool for studying the Nrf2 pathway and its role in neuroprotection and metabolic health. It is not approved for clinical use and is available for research purposes only.
|
| Molecular Formula |
C23H24CLF3N2O3
|
|---|---|
| Molecular Weight |
468.896475791931
|
| Exact Mass |
468.142
|
| CAS # |
2383016-68-8
|
| PubChem CID |
155527528
|
| Appearance |
Light yellow to yellow solid powder
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
32
|
| Complexity |
637
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C(/C1C=CC=CC=1C(F)(F)F)=C\C(C1C=CC(OCC(N2CCN(C)CC2)=O)=CC=1)=O.Cl
|
| InChi Key |
MLBFDNAGDZEBHA-YGCVIUNWSA-N
|
| InChi Code |
InChI=1S/C23H23F3N2O3.ClH/c1-27-12-14-28(15-13-27)22(30)16-31-19-9-6-18(7-10-19)21(29)11-8-17-4-2-3-5-20(17)23(24,25)26;/h2-11H,12-16H2,1H3;1H/b11-8+;
|
| Chemical Name |
(E)-1-[4-[2-(4-methylpiperazin-1-yl)-2-oxoethoxy]phenyl]-3-[2-(trifluoromethyl)phenyl]prop-2-en-1-one;hydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~213.27 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.33 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.33 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (5.33 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1327 mL | 10.6633 mL | 21.3265 mL | |
| 5 mM | 0.4265 mL | 2.1327 mL | 4.2653 mL | |
| 10 mM | 0.2133 mL | 1.0663 mL | 2.1327 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
